ePaperEventsR.AGEmStarMajoritiStarPropertyStarCherishStarCarsifuStarSearchmyStarjobKualiKuntumSuriaFM988FM
WASHINGTON, July 27 (Xinhua) -- A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent COVID-19 in adults has begun in the United States, said a release of the National Institutes of Health (NIH) on Monday.
WASHINGTON, Dec. 28 (Xinhua) -- The Phase 3 trial of another investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Monday.
WASHINGTON, Sept. 30 (Xinhua) -- The Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults, according to a newly published study.
WASHINGTON, Dec. 28 (Xinhua) -- The Phase 3 trial of another investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Monday.
KIGALI, Oct. 17 (Xinhua) -- At least 856 people have been vaccinated against the Marburg virus disease in Rwanda, Health Minister Sabin Nsanzimana announced Thursday.
Elon Musk said a third person has received an implant from his brain-computer interface company Neuralink, one of many groups working to connect the nervous system to machines.
KIGALI, Oct. 18 (Xinhua) -- Outside a public market in Rwanda's capital of Kigali, Innocent Nyirimana, a local resident, waited for his turn to wash his hands before entering the market.
JAKARTA: The World Health Organization (WHO) and the Food and Drug Authority (BPOM) have approved the use of the mpox vaccine in Indonesia, according to the Health Ministry.
LOS ANGLES, Sept. 15 (Xinhua) -- The United States has started the phase 1 clinical trial of a new investigational universal flu vaccine candidate, the U.S. National Institutes of Health (NIH) announced on Friday.
(Reuters) - A man with amyotrophic lateral sclerosis (ALS) who had lost his ability to speak has been able to communicate with a Blackrock Neurotech text-to-speech brain implant, researchers said in one of two new studies showing the promise of brain-computer interfaces for restoring speech in paralyzed patients.
Neuralink Corp, Elon Musk’s brain-computer company, said surgery for its second implant in a human “went well” and the patient is now able to design 3D objects and play video games like Counter-Strike 2.
WASHINGTON, Sept. 1 (Xinhua) -- A multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222 has begun, the U.S. National Institutes of Health (NIH) announced on Monday.
WASHINGTON, Sept. 23 (Xinhua) -- A fourth Phase 3 clinical trial evaluating an investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Wednesday.
WASHINGTON, Sept. 23 (Xinhua) -- A fourth Phase 3 clinical trial evaluating an investigational COVID-19 vaccine has begun enrolling adult volunteers, the U.S. National Institutes of Health (NIH) announced on Wednesday.
WASHINGTON, Sept. 1 (Xinhua) -- Researchers across the United States are stepping up efforts to work out an effective COVID-19 vaccine as another vaccine candidate has started phase 3 clinical trial on Monday.
Netflix has recently unveiled an exciting lineup of films and series from South-East Asia, showcasing new works from Thailand, the Philippines, and Indonesia.
The billionaire, who co-founded Neuralink, did not provide additional details about the patient.
SINGAPORE, Aug 8 (The Straits Times/ANN): Volunteers being screened for Lunar-Cov19's early-stage clinical trial that is set to last till October
CHICAGO, Jan. 27 (Xinhua) -- A study of Washington University School of Medicine in St. Louis suggests that an innovative approach to treating bone tumors, starving cancer cells of the energy they need to grow, may one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects.
WASHINGTON, Jan. 5 (Xinhua) -- A large clinical trial has begun in the United States to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who have mild or moderate COVID-19, the U.S. National Institutes of Health (NIH) announced on Tuesday.
